Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cytomegalovirus
100%
Melanoma
100%
Cancer Vaccine
100%
Tyrosinase-related Protein 2
100%
Human Cytomegalovirus
81%
Antitumor Effect
45%
Vaccination
18%
Tumor Antigen
18%
B16 Melanoma
18%
CD8 T Cells
18%
Glycoprotein
9%
B Cells
9%
T Cells
9%
Gene-deficient Mice
9%
Cytomegalovirus Infection
9%
Cancer Development
9%
Specific Antibodies
9%
CD4 T Cells
9%
Effector Phase
9%
Tumor Challenge
9%
Anti-melanoma
9%
Vaccine Vector
9%
Melanoma Antigens
9%
Long-term Immune Response
9%
Long-term Protection
9%
Therapeutic Vaccination
9%
Tumor Rejection
9%
B16 Cells
9%
Prophylactic Vaccination
9%
Vaccine Response
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cytomegalovirus
100%
Melanoma
100%
Dopachrome Tautomerase
100%
Tumor Vaccine
100%
Murine Cytomegalovirus
81%
Vaccination
36%
Neoplasm
27%
CD8 Antigen
18%
Tumor Antigen
18%
Melanoma B16
18%
Melanoma Antigen
9%
Cytomegalovirus Infection
9%
Glycoprotein L
9%
Immunology and Microbiology
Cytomegalovirus
100%
Murine Cytomegalovirus
100%
Tumor Vaccine
100%
Cytotoxic T-Cell
22%
Tumor Antigen
22%
Glycoprotein
11%
T-Helper Cell
11%
Immune Response
11%
T Cell
11%
Cytomegalovirus Infection
11%
B Cell
11%
Melanoma Antigen
11%
Tumor Rejection
11%